The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC).
 
Julie Nicole Graff
Honoraria - Astellas Medivation; Bayer; Bayer; Bayer; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Sanofi; Valeant/Dendreon
Consulting or Advisory Role - Exelixis
Speakers' Bureau - i3 CME
Research Funding - Janssen Oncology (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Oncoresponse: Exceptional responders
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Merck Sharp & Dohme; Merck Sharp & Dohme; Sanofi
 
Heather H. Cheng
Research Funding - Astellas Medivation (Inst); Clovis Oncology (Inst); Color Genomics Foundation (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Sanofi (Inst)
 
Jacqueline Vuky
Consulting or Advisory Role - Agendia; Eisai; Genomic Health; Merck
Research Funding - Celldex (Inst); Innocrin Pharma (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Joshi J. Alumkal
Consulting or Advisory Role - Janssen Biotech
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Gilead Sciences (Inst); Novartis (Inst); Zenith Epigenetics (Inst)
 
Dustin Kreitner
No Relationships to Disclose
 
Delia Petreaca
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Immunomedics (Inst); Pfizer (Inst)
 
Michael Thomas Schweizer
Consulting or Advisory Role - Janssen
Research Funding - AstraZeneca (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Pfizer (Inst); Roche (Inst); Zenith Epigenetics (Inst)
 
Celestia S. Higano
Honoraria - Astellas Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Blue Earth Diagnostics; Clovis Oncology; Ferring; Hinova Pharmaceuticals; Janssen; Pfizer
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); eFFECTOR Therapeutics (Inst); Emergent BioSolutions (Inst); Ferring (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Blue Earth Diagnostics; Clovis Oncology; Ferring; Hinova Pharmaceuticals; Janssen Oncology; Pfizer
 
Yiyi Chen
Employment - Biotronik International (I)
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Incyte; Janssen; Merck; Pharmacyclics; QED Therapeutics; Seagen
Research Funding - Daiichi Sankyo (Inst); Dendreon (Inst); Merck (Inst); Seagen (Inst); Taicho (Inst)
 
Tomasz M. Beer
Stock and Other Ownership Interests - Arvinas; Salarius Pharmaceuticals
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; Janssen; Janssen Biotech; Merck; Pfizer
Research Funding - Alliance Foundation Trials (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Janssen Research & Development (Inst); Medivation/Astellas (Inst); Oncogenex (Inst); Sotio; Sotio (Inst); Theraclone Sciences (Inst)